NO303374B1 - Kapsel med forsinket frigj°ring - Google Patents

Kapsel med forsinket frigj°ring Download PDF

Info

Publication number: NO303374B1
Authority: NO; Norway
Prior art keywords: capsule; arms; cap; rumen; arm
Prior art date: 1991-04-05

Application number

NO921304A

Other languages

English (en)

Norwegian (no)

Other versions

NO921304L (no

NO921304D0 (no

Inventor

Lionel Barry Lowe

Colin John Mcarthur

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-04-05

Filing date

1992-04-03

Publication date

1998-07-06

1992-04-03 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1992-04-03 Publication of NO921304D0 publication Critical patent/NO921304D0/no

1992-10-06 Publication of NO921304L publication Critical patent/NO921304L/no

1998-07-06 Publication of NO303374B1 publication Critical patent/NO303374B1/no

Links

239000002775 capsule Substances 0.000 title claims abstract description 154
230000003111 delayed effect Effects 0.000 title description 10
239000000203 mixture Substances 0.000 claims abstract description 72
210000004767 rumen Anatomy 0.000 claims abstract description 47
241000282849 Ruminantia Species 0.000 claims abstract description 29
238000007789 sealing Methods 0.000 claims abstract description 17
238000005452 bending Methods 0.000 claims abstract description 12
241001465754 Metazoa Species 0.000 claims abstract description 11
239000011324 bead Substances 0.000 claims abstract description 11
230000014759 maintenance of location Effects 0.000 claims abstract description 9
238000013268 sustained release Methods 0.000 claims abstract description 6
239000012730 sustained-release form Substances 0.000 claims abstract description 6
230000000717 retained effect Effects 0.000 claims abstract description 5
210000003238 esophagus Anatomy 0.000 claims description 20
239000012530 fluid Substances 0.000 claims description 16
239000003795 chemical substances by application Substances 0.000 claims description 13
239000002518 antifoaming agent Substances 0.000 claims description 12
239000004721 Polyphenylene oxide Substances 0.000 claims description 9
239000003242 anti bacterial agent Substances 0.000 claims description 9
229940088710 antibiotic agent Drugs 0.000 claims description 9
239000000314 lubricant Substances 0.000 claims description 9
229920000570 polyether Polymers 0.000 claims description 9
GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 claims description 8
229930191564 Monensin Natural products 0.000 claims description 7
GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 claims description 7
-1 chlorquine Chemical compound 0.000 claims description 7
229960005358 monensin Drugs 0.000 claims description 7
229940124339 anthelmintic agent Drugs 0.000 claims description 5
239000000921 anthelmintic agent Substances 0.000 claims description 5
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims description 5
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims description 5
239000003910 polypeptide antibiotic agent Substances 0.000 claims description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
229930182504 Lasalocid Natural products 0.000 claims description 4
VHKXXVVRRDYCIK-CWCPJSEDSA-N Narasin Chemical compound C[C@H]1C[C@H](C)[C@H]([C@@H](CC)C(O)=O)O[C@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 VHKXXVVRRDYCIK-CWCPJSEDSA-N 0.000 claims description 4
VHKXXVVRRDYCIK-UHFFFAOYSA-N Narasin Natural products CC1CC(C)C(C(CC)C(O)=O)OC1C(C)C(O)C(C)C(=O)C(CC)C1C(C)CC(C)C2(C=CC(O)C3(OC(C)(CC3)C3OC(C)C(O)(CC)CC3)O2)O1 VHKXXVVRRDYCIK-UHFFFAOYSA-N 0.000 claims description 4
KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 claims description 4
239000004189 Salinomycin Substances 0.000 claims description 4
BBMULGJBVDDDNI-OWKLGTHSSA-N lasalocid Chemical compound C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C(O)=O)C[C@](O)(CC)[C@H](C)O1 BBMULGJBVDDDNI-OWKLGTHSSA-N 0.000 claims description 4
229960000320 lasalocid Drugs 0.000 claims description 4
229960001851 narasin Drugs 0.000 claims description 4
229960001548 salinomycin Drugs 0.000 claims description 4
235000019378 salinomycin Nutrition 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
FELYAZAWTURXNF-KWJIWYEDSA-N (E,2S,4R,8S)-8-[(2S,5R,7S,8R,9R)-7-hydroxy-2-[(2R,4S,5S,7R,9S,10R)-2-[(2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-9-[(2S,5S,6R)-5-methoxy-6-methyloxan-2-yl]oxy-4,10-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-2,4,6-trimethyl-5-oxonon-6-enoic acid Chemical compound O1[C@H](C)[C@@H](OC)CC[C@H]1O[C@@H]1[C@@H](C)[C@]2([C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)O[C@@H]([C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](O)C3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)CC2)C1 FELYAZAWTURXNF-KWJIWYEDSA-N 0.000 claims description 3
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 3
RHDSQRNKIIRGBB-UHFFFAOYSA-N 2-[2-hydroxy-6-[[2-[5-[5-(6-hydroxy-4-methoxy-3,5,6-trimethyloxan-2-yl)oxolan-2-yl]oxolan-2-yl]-3,7-dimethoxy-2,4,6-trimethyl-1,10-dioxaspiro[4.5]decan-9-yl]methyl]-5-methoxy-4-(5-methoxy-6-methyloxan-2-yl)oxy-3,5-dimethyloxan-2-yl]propanoic acid Chemical compound COC1C(C)C2(C(C(OC)CC(CC3C(C(OC4OC(C)C(OC)CC4)C(C)C(O)(C(C)C(O)=O)O3)(C)OC)O2)C)OC1(C)C(O1)CCC1C(O1)CCC1C1OC(C)(O)C(C)C(OC)C1C RHDSQRNKIIRGBB-UHFFFAOYSA-N 0.000 claims description 3
239000004184 Avoparcin Substances 0.000 claims description 3
108010081391 Ristocetin Proteins 0.000 claims description 3
108010020588 actaplanin Proteins 0.000 claims description 3
BDNDRNLSLGGULA-UHFFFAOYSA-N actaplanin Chemical compound C=1C2=CC=C(O)C=1C1=C(OC3C(C(O)C(O)C(CO)O3)O)C=C(O)C=C1C(C(=O)OC)NC(=O)C1NC(=O)C2NC(=O)C2NC(=O)C(C=3C=C(C(=C(O)C=3)C)OC=3C(O)=CC=C(C=3)C(N)C(=O)N3)NC(=O)C3CC(C=C3)=CC=C3OC(C=3OC4C(C(O)C(O)C(CO)O4)O)=CC2=CC=3OC(C(=C2)Cl)=CC=C2C1OC1CC(N)C(O)C(C)O1 BDNDRNLSLGGULA-UHFFFAOYSA-N 0.000 claims description 3
229950002379 actaplanin Drugs 0.000 claims description 3
108010053278 avoparcin Proteins 0.000 claims description 3
JWFVWARSGMYXRN-HTQQBIQNSA-N avoparcin Chemical compound O([C@H]1[C@H](C(N[C@H](C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(N[C@H](C4=CC(O)=CC(O)=C4C=4C(O)=CC=C3C=4)C(O)=O)=O)CC3=C(O[C@@H]4O[C@@H](C)[C@H](O)[C@H](N)C4)C=C(C(=C3)Cl)OC=3C=C2C=C(C=3O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)OC2=CC=C1C=C2)C=1C=CC(O)=CC=1)=O)NC(=O)[C@@H](NC)C=1C=CC(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)=CC=1)[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@H]1O JWFVWARSGMYXRN-HTQQBIQNSA-N 0.000 claims description 3
235000019377 avoparcin Nutrition 0.000 claims description 3
229950001335 avoparcin Drugs 0.000 claims description 3
BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 claims description 3
230000006378 damage Effects 0.000 claims description 3
DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 claims description 3
229960003439 mebendazole Drugs 0.000 claims description 3
DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 claims description 3
238000003825 pressing Methods 0.000 claims description 3
229950004257 ristocetin Drugs 0.000 claims description 3
239000004094 surface-active agent Substances 0.000 claims description 3
WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 claims description 3
229960004546 thiabendazole Drugs 0.000 claims description 3
239000004308 thiabendazole Substances 0.000 claims description 3
235000010296 thiabendazole Nutrition 0.000 claims description 3
ZITSQIZMRMDQLE-SJSJOXFOSA-N (2R)-2-[(2R,3S,6R)-6-[[(2S,4R,5R,6R,7R,9R)-2-[(2R,5S)-5-[(2R,3S,5R)-5-[(2S,3S,5R,6S)-6-hydroxy-3,5,6-trimethyloxan-2-yl]-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-7-methoxy-2,4,6-trimethyl-1,10-dioxaspiro[4.5]decan-9-yl]methyl]-3-methyloxan-2-yl]propanoic acid Chemical compound CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@@H](O2)[C@@H](C)C(O)=O)O[C@]2(O[C@@](C)(C[C@H]2C)[C@H]2CC[C@](C)(O2)[C@@H]2O[C@H](C[C@@H]2C)[C@H]2O[C@](C)(O)[C@H](C)C[C@@H]2C)[C@@H]1C ZITSQIZMRMDQLE-SJSJOXFOSA-N 0.000 claims description 2
QZVSDERYSHAHPU-LFEMCTADSA-N (2r)-2-[(2s,3r,4s,5s,6s)-2-hydroxy-6-[[(2r,3r,4r,5s,6r,7r,9s)-2-[(5s)-5-[(2r,5r)-5-[(3s,5r,6s)-6-hydroxy-3,5,6-trimethyloxan-2-yl]oxolan-2-yl]oxolan-2-yl]-3,7-dimethoxy-2,4,6-trimethyl-1,10-dioxaspiro[4.5]decan-9-yl]methyl]-4-methoxy-5-[(2s,5s,6r)-5-metho Chemical compound C1([C@H]2CC[C@@H](O2)[C@@H]2CCC(O2)[C@@]2(C)O[C@]3([C@H](C)[C@H]2OC)[C@@H]([C@H](OC)C[C@@H](C[C@H]2[C@]([C@@H](OC)[C@@H](C)[C@@](O)([C@@H](C)C(O)=O)O2)(C)O[C@@H]2O[C@H](C)[C@@H](OC)CC2)O3)C)O[C@](C)(O)[C@H](C)C[C@@H]1C QZVSDERYSHAHPU-LFEMCTADSA-N 0.000 claims description 2
PYUBINRDIXNWEP-BSSZEUCBSA-N (2r)-2-[(2s,3s,6r)-6-[(2r,3s)-3-[(2r,5s,6r)-6-[[(2r,3s,6r)-6-[(1r)-1-[(2s,5s)-5-[(2r,5s)-5-[(2r,5r,6s)-6-ethyl-5-hydroxy-5-methyloxan-2-yl]-2-hydroxyoxolan-2-yl]-5-methyloxolan-2-yl]ethyl]-6-hydroxy-3-methyloxan-2-yl]methyl]-6-hydroxy-5-methyloxan-2-yl]-2 Chemical compound C1C[C@](O)(C)[C@H](CC)O[C@H]1[C@H]1O[C@@](O)([C@@]2(C)O[C@@H](CC2)[C@@H](C)[C@]2(O)O[C@H](C[C@]3(O)[C@H](CC[C@@H](O3)[C@@H](C)[C@H](O)C[C@@H]3O[C@@H]([C@@H](C)CC3)[C@@H](C)C(O)=O)C)[C@@H](C)CC2)CC1 PYUBINRDIXNWEP-BSSZEUCBSA-N 0.000 claims description 2
VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 claims description 2
ZNBNBTIDJSKEAM-NISBWGIBSA-N (2s,3r,4r)-4-[(2s,5r,7s,8r,9s)-7-hydroxy-2-[(2r,5s)-5-[(2r,3s,5r)-5-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-2-methyl-3-propanoyloxypentanoic a Chemical compound C1[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC(=O)CC)[C@H](C)C(O)=O)O[C@]11O[C@](C)([C@@H]2O[C@@](C)(CC2)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)CC1 ZNBNBTIDJSKEAM-NISBWGIBSA-N 0.000 claims description 2
LQFPDTISEHAMNQ-JRSQRZRGSA-N (e,2s,4r,8s)-8-[(2s,5r,6r,7r,9s)-2-[(2r,4s,5r,6r,9r)-2-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-4,6-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-7-[(2r,5s,6r)-5-methoxy-6-methyloxan-2-yl]oxy-2,6-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl Chemical compound O1[C@H](C)[C@@H](OC)CC[C@@H]1O[C@H]1[C@@H](C)[C@@]2(O[C@@](C)(CC2)[C@@H]2O[C@@]3([C@H](C[C@@H](O3)[C@@H]3[C@H](C[C@@H](C)[C@](O)(CO)O3)C)C)[C@H](C)CC2)O[C@H]([C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)C1 LQFPDTISEHAMNQ-JRSQRZRGSA-N 0.000 claims description 2
WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims description 2
CYEJMVLDXAUOPN-UHFFFAOYSA-N 2-dodecylphenol Chemical compound CCCCCCCCCCCCC1=CC=CC=C1O CYEJMVLDXAUOPN-UHFFFAOYSA-N 0.000 claims description 2
SWDXALWLRYIJHK-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;piperazine Chemical compound C1CNCCN1.OC(=O)CC(O)(C(O)=O)CC(O)=O SWDXALWLRYIJHK-UHFFFAOYSA-N 0.000 claims description 2
MJNGPLNGGSOMFS-UHFFFAOYSA-N 2-methyl-n-(2-methyltetrazol-5-yl)propanamide Chemical compound CC(C)C(=O)NC=1N=NN(C)N=1 MJNGPLNGGSOMFS-UHFFFAOYSA-N 0.000 claims description 2
NZHCPUBOSWFGNA-MKODDJJXSA-N 3-chloro-2-[(2s,4r,5s,6s,8r)-8-[(1r,2r,3r,7r,9s,10s,12r,15r)-3-[(2r,4r)-5-ethoxycarbonyl-4-hydroxyoxolan-2-yl]-15-hydroxy-2-methoxy-1,3,10,12-tetramethyl-4,6,8-trioxadispiro[4.1.5^{7}.3^{5}]pentadec-13-en-9-yl]-5-hydroxy-4,6-dimethyl-7-oxononan-2-yl]-6-hy Chemical compound C1[C@@H](O)C(C(=O)OCC)O[C@H]1[C@]1(C)[C@H](OC)[C@@H](C)C2([C@@H](C=C[C@@]3([C@@H](C[C@H](C)[C@@H]([C@@H](C)C(=O)[C@@H](C)[C@@H](O)[C@H](C)C[C@H](C)C=4C(=C(O)C(C)=CC=4Cl)C(O)=O)O3)C)O2)O)O1 NZHCPUBOSWFGNA-MKODDJJXSA-N 0.000 claims description 2
WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 claims description 2
XZJLJFYPIJKWCY-ANXQGEBNSA-N 6-[(3r,4s,5s,7r)-7-[(2s,3s,5s)-5-ethyl-5-[(2r,5s)-5-ethyl-5-[(1r)-1-hydroxyethyl]oxolan-2-yl]-3-methyloxolan-2-yl]-4-hydroxy-3,5-dimethyl-6-oxononyl]-2-hydroxy-3-methylbenzoic acid Chemical compound C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C(O)=O)C[C@@](CC)([C@@H](C)O)O1 XZJLJFYPIJKWCY-ANXQGEBNSA-N 0.000 claims description 2
239000005660 Abamectin Substances 0.000 claims description 2
WWDHGOLBPBWCNJ-UHFFFAOYSA-N Alborixin Natural products C1CC(O)(C)C(CC)OC1C1(C)OC(O)(C2(C)OC(CC2)C(O)C2(O)C(CC(C)C(CC3(O)C(CCC(O3)C(C)C(O)CC3C(CC(C)C(C(C)C(O)=O)O3)C)C)O2)C)C(C)C1 WWDHGOLBPBWCNJ-UHFFFAOYSA-N 0.000 claims description 2
241000723347 Cinnamomum Species 0.000 claims description 2
MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 claims description 2
PGNKBEARDDELNB-UHFFFAOYSA-N Diethylcarbamazine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCN(CC)C(=O)N1CCN(C)CC1 PGNKBEARDDELNB-UHFFFAOYSA-N 0.000 claims description 2
ZITSQIZMRMDQLE-UHFFFAOYSA-N Grisorixin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(C)(O)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 ZITSQIZMRMDQLE-UHFFFAOYSA-N 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
RWWSBGHRGAQGJE-UHFFFAOYSA-N Laidlomycin Natural products CC(C(CCC(=O)O)C(C)C(=O)O)C1OC2(CCC(C)(O2)C3CCC(C)(O3)C4OC(CC4C)C5OC(O)(CO)C(C)CC5C)CC(O)C1C RWWSBGHRGAQGJE-UHFFFAOYSA-N 0.000 claims description 2
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 2
KTQFYFLZDLTLAH-UHFFFAOYSA-N Lysocellin Natural products CCC(O)C1(CC)CC(C)C(O)(O1)C2(C)CC(C)C(O2)C(CC)C(=O)C(C)C(O)C(C)C3OC(O)(CC(=O)O)C(C)CC3C KTQFYFLZDLTLAH-UHFFFAOYSA-N 0.000 claims description 2
KRJBAINQJPYZJX-UHFFFAOYSA-N Mutalomycin Natural products COC1C(C)C(CC2OC3(CCC(C)(O3)C4CCC(C)(O4)C5OC(CC5C)C6OC(C)(O)C(C)CC6C)CC(O)C2C)OC(O)(C(C)C(=O)O)C1C KRJBAINQJPYZJX-UHFFFAOYSA-N 0.000 claims description 2
RDXLYGJSWZYTFJ-UHFFFAOYSA-N Niridazole Chemical compound S1C([N+](=O)[O-])=CN=C1N1C(=O)NCC1 RDXLYGJSWZYTFJ-UHFFFAOYSA-N 0.000 claims description 2
CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical group ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 claims description 2
AQXXZDYPVDOQEE-MXDQRGINSA-N Pyrantel pamoate Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 AQXXZDYPVDOQEE-MXDQRGINSA-N 0.000 claims description 2
OOPDAHSJBRZRPH-UHFFFAOYSA-L Pyrvinium pamoate Chemical compound C1=CC2=CC(N(C)C)=CC=C2[N+](C)=C1C=CC(=C1C)C=C(C)N1C1=CC=CC=C1.C1=CC2=CC(N(C)C)=CC=C2[N+](C)=C1C=CC(=C1C)C=C(C)N1C1=CC=CC=C1.C12=CC=CC=C2C=C(C([O-])=O)C(O)=C1CC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 OOPDAHSJBRZRPH-UHFFFAOYSA-L 0.000 claims description 2
QZVSDERYSHAHPU-UHFFFAOYSA-N Septamycin Natural products COC1C(C)C2(C(C(OC)CC(CC3C(C(OC)C(C)C(O)(C(C)C(O)=O)O3)(C)OC3OC(C)C(OC)CC3)O2)C)OC1(C)C(O1)CCC1C(O1)CCC1C1OC(C)(O)C(C)CC1C QZVSDERYSHAHPU-UHFFFAOYSA-N 0.000 claims description 2
WWDHGOLBPBWCNJ-GXXSWWTOSA-N alborixin Chemical compound C1C[C@](O)(C)[C@H](CC)O[C@H]1[C@@]1(C)O[C@@](O)([C@@]2(C)O[C@@H](CC2)[C@@H](O)[C@@]2(O)[C@@H](C[C@H](C)[C@@H](C[C@]3(O)[C@H](CC[C@@H](O3)[C@@H](C)[C@H](O)C[C@H]3[C@@H](C[C@H](C)[C@@H]([C@@H](C)C(O)=O)O3)C)C)O2)C)[C@H](C)C1 WWDHGOLBPBWCNJ-GXXSWWTOSA-N 0.000 claims description 2
WRIDGMJGKDWAJY-UHFFFAOYSA-H antimony(3+);1,4-dihydroxy-1,4-dioxobutane-2,3-dithiolate Chemical compound S1C(C(O)=O)C(C(O)=O)S[Sb]1SC(C(O)=O)C(C(=O)O)S[Sb]1SC(C(O)=O)C(C(O)=O)S1 WRIDGMJGKDWAJY-UHFFFAOYSA-H 0.000 claims description 2
229960000254 bephenium Drugs 0.000 claims description 2
JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 claims description 2
229960002326 bithionol Drugs 0.000 claims description 2
229920001400 block copolymer Polymers 0.000 claims description 2
MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims description 2
235000017803 cinnamon Nutrition 0.000 claims description 2
229960003887 dichlorophen Drugs 0.000 claims description 2
229960004837 diethylcarbamazine citrate Drugs 0.000 claims description 2
AXRWJSAOLNNBNI-UHFFFAOYSA-L disodium;2-[(4-carbamoylphenyl)-(carboxylatomethylsulfanyl)arsanyl]sulfanylacetate Chemical compound [Na+].[Na+].NC(=O)C1=CC=C([As](SCC([O-])=O)SCC([O-])=O)C=C1 AXRWJSAOLNNBNI-UHFFFAOYSA-L 0.000 claims description 2
VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 claims description 2
229960003258 hexylresorcinol Drugs 0.000 claims description 2
LOEQGPPJCCUXEJ-UHFFFAOYSA-N hycanthone mesylate Chemical compound CS(O)(=O)=O.S1C2=CC=CC=C2C(=O)C2=C1C(CO)=CC=C2NCCN(CC)CC LOEQGPPJCCUXEJ-UHFFFAOYSA-N 0.000 claims description 2
229960004561 laidlomycin Drugs 0.000 claims description 2
229960001614 levamisole Drugs 0.000 claims description 2
FBQPGGIHOFZRGH-UHFFFAOYSA-N lucanthone Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC FBQPGGIHOFZRGH-UHFFFAOYSA-N 0.000 claims description 2
KTQFYFLZDLTLAH-DESDHLEASA-N lysocellin Chemical compound O1[C@]([C@@H](O)CC)(CC)C[C@@H](C)[C@]1(O)[C@@]1(C)O[C@H]([C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CC(O)=O)O2)C)[C@@H](C)C1 KTQFYFLZDLTLAH-DESDHLEASA-N 0.000 claims description 2
229960000901 mepacrine Drugs 0.000 claims description 2
WWEDNBWYGGJQOV-RIWLGXEFSA-N mutalomycin Chemical compound O1[C@@](O)([C@H](C)C(O)=O)[C@H](C)[C@@H](OC)[C@@H](C)[C@H]1[C@H](C)[C@@H]1[C@H](C)[C@@H](O)C[C@@]2(O[C@@](C)(CC2)[C@@H]2O[C@@](C)(CC2)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@@](C)(O)O2)C)C)O1 WWEDNBWYGGJQOV-RIWLGXEFSA-N 0.000 claims description 2
IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims description 2
229960001920 niclosamide Drugs 0.000 claims description 2
RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 claims description 2
229960005130 niridazole Drugs 0.000 claims description 2
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
229950000688 phenothiazine Drugs 0.000 claims description 2
229960000718 piperazine citrate Drugs 0.000 claims description 2
AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 claims description 2
229940111695 potassium tartrate Drugs 0.000 claims description 2
239000001472 potassium tartrate Substances 0.000 claims description 2
235000011005 potassium tartrates Nutrition 0.000 claims description 2
229960000996 pyrantel pamoate Drugs 0.000 claims description 2
229960001077 pyrvinium pamoate Drugs 0.000 claims description 2
GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims description 2
229920005604 random copolymer Polymers 0.000 claims description 2
150000004671 saturated fatty acids Chemical class 0.000 claims description 2
229950011008 tetrachloroethylene Drugs 0.000 claims description 2
150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 claims 2
QFHLVPYVNFSTBE-SMAIMEEGSA-N (2r)-2-hydroxy-2-[(2s,3s,4s,5s,6s)-2-hydroxy-6-[[(2r,3r,4r,5s,6r,7r,9s)-2-[(2r,5s)-5-[(2r,5r)-5-[(2s,3s,4s,5r,6s)-6-hydroxy-4-[(2r,5s,6r)-5-methoxy-6-methyloxan-2-yl]oxy-3,5,6-trimethyloxan-2-yl]oxolan-2-yl]oxolan-2-yl]-3,7-dimethoxy-2,4,6-trimethyl-1,10- Chemical compound O([C@@H]1[C@@H](C)[C@@](C)(O)O[C@@H]([C@H]1C)[C@H]1CC[C@@H](O1)[C@@H]1CC[C@@H](O1)[C@@]1(C)O[C@]2([C@H](C)[C@H]1OC)[C@@H]([C@H](OC)C[C@@H](C[C@H]1[C@]([C@@H](OC)[C@H](C)[C@@](O)([C@@H](O)C(O)=O)O1)(C)OC)O2)C)[C@H]1CC[C@H](OC)[C@@H](C)O1 QFHLVPYVNFSTBE-SMAIMEEGSA-N 0.000 claims 1
XZJAKURZQBNKKX-QFQDJZPHSA-N (3e)-3-[(2s)-1-hydroxy-2-[(1s,2s,6r)-2-[(e)-3-hydroxy-2-[(2r,3r,6s)-6-[(e,3s)-3-[(2r,3s,5r)-5-[(1s)-1-methoxyethyl]-3-methyloxolan-2-yl]but-1-enyl]-3-methyloxan-2-yl]prop-1-enyl]-6-methylcyclohexyl]propylidene]oxolane-2,4-dione Chemical compound O1[C@@H]([C@H](C)OC)C[C@H](C)[C@@H]1[C@@H](C)\C=C\[C@H]1O[C@@H](C(\CO)=C\[C@@H]2[C@H]([C@H](C)CCC2)[C@H](C)C(\O)=C\2C(OCC/2=O)=O)[C@H](C)CC1 XZJAKURZQBNKKX-QFQDJZPHSA-N 0.000 claims 1
HIYAVKIYRIFSCZ-CVXKHCKVSA-N Calcimycin Chemical compound CC([C@H]1OC2([C@@H](C[C@H]1C)C)O[C@H]([C@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-CVXKHCKVSA-N 0.000 claims 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 claims 1
AVWWVJUMXRXPNF-UHFFFAOYSA-N bephenium Chemical compound C=1C=CC=CC=1C[N+](C)(C)CCOC1=CC=CC=C1 AVWWVJUMXRXPNF-UHFFFAOYSA-N 0.000 claims 1
JZZIHCLFHIXETF-UHFFFAOYSA-N dimethylsilicon Chemical group C[Si]C JZZIHCLFHIXETF-UHFFFAOYSA-N 0.000 claims 1
BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 claims 1
239000002460 polyether antibiotic agent Substances 0.000 claims 1
230000002787 reinforcement Effects 0.000 claims 1
229950002881 tetronasin Drugs 0.000 claims 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
230000002035 prolonged effect Effects 0.000 abstract 1
238000009472 formulation Methods 0.000 description 28
238000000034 method Methods 0.000 description 14
241000283690 Bos taurus Species 0.000 description 8
241001494479 Pecora Species 0.000 description 8
229920001296 polysiloxane Polymers 0.000 description 7
239000000463 material Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
239000004480 active ingredient Substances 0.000 description 4
230000000507 anthelmentic effect Effects 0.000 description 4
108010015899 Glycopeptides Proteins 0.000 description 3
102000002068 Glycopeptides Human genes 0.000 description 3
241000244206 Nematoda Species 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
239000000126 substance Substances 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
150000004657 carbamic acid derivatives Chemical class 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
201000003872 goiter Diseases 0.000 description 2
239000007952 growth promoter Substances 0.000 description 2
239000002555 ionophore Substances 0.000 description 2
230000000236 ionophoric effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
OPXLLQIJSORQAM-UHFFFAOYSA-N mebendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(=O)C1=CC=CC=C1 OPXLLQIJSORQAM-UHFFFAOYSA-N 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
XOIQMTLWECTKJL-FBZUZRIGSA-M sodium;(2s,3r,4s)-4-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-ethyl-5-[(2r,3s,5r)-5-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]oxolan-2-yl]-7-hydroxy-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methylpentanoate Chemical compound [Na+].C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C([O-])=O)O2 XOIQMTLWECTKJL-FBZUZRIGSA-M 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
RAOCRURYZCVHMG-UHFFFAOYSA-N N-(6-propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCOC1=CC=C2N=C(NC(=O)OC)NC2=C1 RAOCRURYZCVHMG-UHFFFAOYSA-N 0.000 description 1
RUSIZKKQGFQEHZ-UHFFFAOYSA-N OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O RUSIZKKQGFQEHZ-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
XSBSGLXIQBCTKN-SARHNJKISA-N X-206 Chemical compound C1C[C@](O)(C)[C@H](CC)O[C@H]1[C@@]1(C)O[C@@](O)([C@@]2(C)O[C@@H](CC2)[C@@H](O)[C@@]2(O)[C@@H](C[C@H](C)[C@@H](C[C@]3(O)[C@H](CC[C@@H](O3)[C@@H](C)[C@H](O)C[C@@H]3O[C@@H]([C@@H](C)CC3)[C@@H](C)C(O)=O)C)O2)C)[C@H](C)C1 XSBSGLXIQBCTKN-SARHNJKISA-N 0.000 description 1
XSBSGLXIQBCTKN-UHFFFAOYSA-N X-206 Natural products C1CC(O)(C)C(CC)OC1C1(C)OC(O)(C2(C)OC(CC2)C(O)C2(O)C(CC(C)C(CC3(O)C(CCC(O3)C(C)C(O)CC3OC(C(C)CC3)C(C)C(O)=O)C)O2)C)C(C)C1 XSBSGLXIQBCTKN-UHFFFAOYSA-N 0.000 description 1
IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
JHSNLCCMZMGXLK-UHFFFAOYSA-N [3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COCC(O)CO JHSNLCCMZMGXLK-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
229960002669 albendazole Drugs 0.000 description 1
HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
150000001556 benzimidazoles Chemical class 0.000 description 1
PMPQCPQAHTXCDK-UHFFFAOYSA-M benzyl-dimethyl-(2-phenoxyethyl)azanium;3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1.C=1C=CC=CC=1C[N+](C)(C)CCOC1=CC=CC=C1 PMPQCPQAHTXCDK-UHFFFAOYSA-M 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
229960003475 cambendazole Drugs 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
238000005266 casting Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
HDDSHPAODJUKPD-UHFFFAOYSA-N fenbendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 HDDSHPAODJUKPD-UHFFFAOYSA-N 0.000 description 1
229960005473 fenbendazole Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
229940068939 glyceryl monolaurate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229960004454 oxfendazole Drugs 0.000 description 1
BEZZFPOZAYTVHN-UHFFFAOYSA-N oxfendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1S(=O)C1=CC=CC=C1 BEZZFPOZAYTVHN-UHFFFAOYSA-N 0.000 description 1
229960002762 oxibendazole Drugs 0.000 description 1
239000002297 parasiticide Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
QZWHWHNCPFEXLL-UHFFFAOYSA-N propan-2-yl n-[2-(1,3-thiazol-4-yl)-3h-benzimidazol-5-yl]carbamate Chemical compound N1C2=CC(NC(=O)OC(C)C)=CC=C2N=C1C1=CSC=N1 QZWHWHNCPFEXLL-UHFFFAOYSA-N 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
239000001589 sorbitan tristearate Substances 0.000 description 1
235000011078 sorbitan tristearate Nutrition 0.000 description 1
229960004129 sorbitan tristearate Drugs 0.000 description 1
IETSNGDRGBQDKY-UHFFFAOYSA-N tetracosan-12-ol Chemical compound CCCCCCCCCCCCC(O)CCCCCCCCCCC IETSNGDRGBQDKY-UHFFFAOYSA-N 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0068—Rumen, e.g. rumen bolus

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Medicinal Preparation (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Fodder In General (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Feed For Specific Animals (AREA)
Manufacturing Of Micro-Capsules (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)
Medicines Containing Plant Substances (AREA)

NO921304A 1991-04-05 1992-04-03 Kapsel med forsinket frigj°ring NO303374B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPK549091		1991-04-05
AUPK839491		1991-09-16

Publications (3)

Publication Number	Publication Date
NO921304D0 NO921304D0 (no)	1992-04-03
NO921304L NO921304L (no)	1992-10-06
NO303374B1 true NO303374B1 (no)	1998-07-06

Family

ID=25644028

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO921304A NO303374B1 (no)	1991-04-05	1992-04-03	Kapsel med forsinket frigj°ring

Country Status (26)

Country	Link
US (2)	US5277912A (cs)
EP (2)	EP0507629B1 (cs)
JP (2)	JP3356796B2 (cs)
KR (1)	KR100205666B1 (cs)
CN (3)	CN1056278C (cs)
AT (1)	ATE147972T1 (cs)
AU (2)	AU650113B2 (cs)
BR (1)	BR9201217A (cs)
CA (1)	CA2065084C (cs)
CZ (1)	CZ282457B6 (cs)
DE (1)	DE69216891T2 (cs)
DK (1)	DK0507629T3 (cs)
ES (1)	ES2096717T3 (cs)
FI (3)	FI114686B (cs)
GR (1)	GR3022824T3 (cs)
HU (1)	HU217965B (cs)
IE (2)	IE20010191A1 (cs)
IL (9)	IL118193A (cs)
MX (1)	MX9201539A (cs)
MY (2)	MY135579A (cs)
NO (1)	NO303374B1 (cs)
NZ (5)	NZ242225A (cs)
PT (2)	PT100345B (cs)
RU (1)	RU2114577C1 (cs)
TW (1)	TW404830B (cs)
YU (2)	YU49098B (cs)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU734462B2 (en) *	1991-04-05	2001-06-14	Eli Lilly And Company	Sustained release capsule and formulations
AUPM430894A0 (en) *	1994-03-08	1994-03-31	Eli Lilly And Company	A formulation and methods of treatment (1)
US5466233A (en) *	1994-04-25	1995-11-14	Escalon Ophthalmics, Inc.	Tack for intraocular drug delivery and method for inserting and removing same
KR960016882A (ko) *	1994-11-01	1996-06-17	강재헌	치주염치료를 위한 서방출형 생분해성 제제
AU757071B2 (en) *	1996-04-04	2003-01-30	Msd K.K.	Method of treating heart failure with endothelin antagonists
US6086633A (en) *	1996-10-17	2000-07-11	Eli Lilly And Company	Method for preserving animal hides
ES2174114T3 (es) *	1996-10-17	2002-11-01	Lilly Co Eli	Procedimiento para conservar pieles de animales.
CN1099283C (zh) *	1997-05-28	2003-01-22	内蒙古巴彦淖尔盟畜牧兽医科学研究所	缓释丸及其制剂
US6245042B1 (en)	1997-08-27	2001-06-12	Science Incorporated	Fluid delivery device with temperature controlled energy source
EP1021137B1 (en) *	1997-10-10	2007-08-08	Bioniche Life Sciences Inc.	Drug delivery system
US6183461B1 (en)	1998-03-11	2001-02-06	Situs Corporation	Method for delivering a medication
US6361552B1 (en)	1998-03-25	2002-03-26	Michael J. Badalamenti	Teething gel applicator with cutter, and burstable ampule and method of making the same
US6759393B1 (en)	1999-04-12	2004-07-06	Pfizer Inc.	Growth hormone and growth hormone releasing hormone compositions
WO2000064513A1 (en)	1999-04-23	2000-11-02	Situs Corporation	Pressure responsive valve for use with an intravesical infuser
GB9930000D0 (en)	1999-12-21	2000-02-09	Phaeton Research Ltd	An ingestible device
GB9930001D0 (en)	1999-12-21	2000-02-09	Phaeton Research Ltd	An ingestible device
EP1404297B1 (en)	2001-06-12	2011-04-27	The Johns Hopkins University School Of Medicine	Reservoir device for intraocular drug delivery
AUPR839001A0 (en) *	2001-10-19	2001-11-15	Eli Lilly And Company	Dosage form, device and methods of treatment
CA2479350A1 (en) *	2002-03-15	2003-09-25	Cypress Bioscience, Inc.	Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US6974587B2 (en) *	2002-05-08	2005-12-13	Aircom Manufacturing, Inc.	Intraruminal device
US20060003004A1 (en) *	2002-10-25	2006-01-05	Collegium Pharmaceutical, Inc.	Pulsatile release compositions of milnacipran
US20040121010A1 (en) *	2002-10-25	2004-06-24	Collegium Pharmaceutical, Inc.	Pulsatile release compositions of milnacipran
WO2004067039A1 (en) *	2003-01-28	2004-08-12	Collegium Pharmaceutical, Inc.	Multiparticulate compositions of milnacipran for oral administration
DE10310825B3 (de) *	2003-03-07	2004-08-19	Fachhochschule Jena	Anordnung zur ferngesteuerten Freisetzung von Wirkstoffen
US20050038315A1 (en) *	2003-08-12	2005-02-17	Slo-Flo Ltd.	Motorized syringe particularly useful for intra-uterine insemination
US6949091B2 (en) *	2003-11-17	2005-09-27	Pin Huang Ting	Method for inserting solid object into skin
US7350479B2 (en) *	2004-09-10	2008-04-01	United States Of America As Represented By The Secretary Of The Army	System and method for controlling growth of aquatic plants utilizing bio-eroding means implanted in triploid grass carp
US20070212397A1 (en) *	2005-09-15	2007-09-13	Roth Daniel B	Pharmaceutical delivery device and method for providing ocular treatment
NZ543314A (en) *	2005-10-28	2007-08-31	Interag	A delivery system where the driving substance contains the active component
US20090099062A1 (en) *	2007-05-31	2009-04-16	Ethan Lee	Pyrvinium For The Treatment of Cancer
AU2010208046B2 (en)	2009-01-29	2014-10-02	Forsight Vision4, Inc.	Posterior segment drug delivery
US8623395B2 (en)	2010-01-29	2014-01-07	Forsight Vision4, Inc.	Implantable therapeutic device
BR112012002271B1 (pt)	2009-07-31	2020-06-16	Merial, Inc	Cápsulas de liberação sustentada
NZ600845A (en) *	2009-12-17	2014-08-29	Merial Ltd	Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles
WO2013022801A1 (en)	2011-08-05	2013-02-14	Forsight Vision4, Inc.	Small molecule delivery with implantable therapeutic device
AU2011285548B2 (en)	2010-08-05	2014-02-06	Forsight Vision4, Inc.	Combined drug delivery methods and apparatus
CN103209664A (zh)	2010-08-05	2013-07-17	弗赛特影像4股份有限公司	可植入的治疗装置
EP3861969A1 (en)	2010-08-05	2021-08-11	ForSight Vision4, Inc.	Injector apparatus for drug delivery
WO2012068549A2 (en)	2010-11-19	2012-05-24	Forsight Vision4, Inc.	Therapeutic agent formulations for implanted devices
BRPI1102284A2 (pt)	2011-05-23	2013-11-05	Grasp Ind E Com Ltda	Aditivo para a nutrição animal a base de nitratos e sulfatos encapsulados para a redução da emissão de metano proveniente da fermentação ruminal
NZ593497A (en) *	2011-06-16	2013-01-25	Kahne Ltd	Animal digestion monitoring system with bolus having a transmitter and designed to be retained in the dorsal sac of the rumen
US10398592B2 (en)	2011-06-28	2019-09-03	Forsight Vision4, Inc.	Diagnostic methods and apparatus
PT2755600T (pt)	2011-09-16	2021-04-19	Forsight Vision4 Inc	Aparelhos de troca de fluidos
WO2013116061A1 (en)	2012-02-03	2013-08-08	Forsight Vision4, Inc.	Insertion and removal methods and apparatus for therapeutic devices
RU2522267C2 (ru) *	2012-08-28	2014-07-10	Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова Министерства сельского хозяйства Российской Федерации	Способ инкапсуляции фенбендазола
WO2014152959A1 (en)	2013-03-14	2014-09-25	Forsight Vision4, Inc.	Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
RU2522229C1 (ru) *	2013-03-26	2014-07-10	Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Юго-Западный государственный университет" (ЮЗ ГУ)	Способ инкапсуляции фенбендазола
CN105246438B (zh)	2013-03-28	2018-01-26	弗赛特影像4股份有限公司	用于输送治疗物质的眼科植入物
RU2545742C2 (ru) *	2013-07-23	2015-04-10	Александр Александрович Кролевец	Способ инкапсуляции лактобифадола
RU2555782C1 (ru) *	2014-03-03	2015-07-10	Александр Александрович Кролевец	Способ получения нанокапсул сульфата глюкозамина в конжаковой камеди в гексане
RU2555055C1 (ru) *	2014-03-18	2015-07-10	Александр Александрович Кролевец	Способ получения нанокапсул сульфата глюкозамина в ксантановой камеди
RU2558084C1 (ru) *	2014-03-18	2015-07-27	Александр Александрович Кролевец	Способ получения нанокапсул аспирина в каррагинане
RU2557941C1 (ru) *	2014-03-20	2015-07-27	Александр Александрович Кролевец	Способ получения нанокапсул аспирина в альгинате натрия
RU2554759C1 (ru) *	2014-04-07	2015-06-27	Александр Александрович Кролевец	Способ получения нанокапсул лозартана калия
ES2803102T3 (es)	2014-07-15	2021-01-22	Forsight Vision4 Inc	Dispositivo de administración de implante ocular
RU2017105844A (ru)	2014-08-08	2018-09-11	Форсайт Вижн4, Инк.	Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения
CN110478119B (zh)	2014-11-10	2022-04-15	弗赛特影像4股份有限公司	可膨胀药物递送装置和使用方法
WO2017087902A1 (en)	2015-11-20	2017-05-26	Forsight Vision4, Inc.	Porous structures for extended release drug delivery devices
CN113017981B (zh)	2016-04-05	2023-07-25	弗赛特影像4股份有限公司	药物递送装置
USD898907S1 (en) *	2017-08-25	2020-10-13	Argenta Manufacturing Limited	Wing of an intraruminal device
US11793751B2 (en) *	2017-09-20	2023-10-24	Lyndra Therapeutics, Inc.	Encapsulation of gastric residence systems
CN111655206B (zh)	2017-11-21	2022-10-14	弗赛特影像4股份有限公司	用于可扩展端口递送系统的流体交换装置及使用方法
EP3758647B1 (en) *	2018-02-26	2024-07-31	Argenta Innovation Limited	Intra-ruminal device
CN108211107B (zh) *	2018-03-01	2023-08-15	中南民族大学	一种针对穴位持续给药的压力可控式微泡贴及制备方法
DK3545937T3 (da) *	2018-03-28	2022-08-15	Hoefliger Harro Verpackung	Kapselbøsning til stikkapsler og bøsningssystem
JP7709914B2 (ja) *	2018-09-10	2025-07-17	アージェンタ・イノベイション・リミテッド	送達装置における放出制御製剤
MX2021010972A (es) *	2019-03-14	2021-10-13	Esocap Ag	Forma de dosificacion farmaceutica para la aplicacion a membranas mucosas y metodos para producir las mismas.
EP4013348B1 (en) *	2019-08-14	2023-12-20	Elanco Tiergesundheit AG	New wing protector for winged capsule and method of using same
JP7721544B2 (ja) *	2020-02-07	2025-08-12	エランコ・アニマル・ヘルス・インコーポレイテッド	翼状カプセル
HUE067496T2 (hu)	2020-12-08	2024-10-28	Ruminant Biotech Corp Ltd	Az állatoknak szánt anyagok bejuttatására szolgáló eszközök és módszerek fejlesztése
USD1033637S1 (en)	2022-01-24	2024-07-02	Forsight Vision4, Inc.	Fluid exchange device
CA3246281A1 (en) *	2022-03-31	2023-10-05	Elanco Us Inc.	WINGED CAPSULE DEVICES AND METHODS
TW202600188A (zh) *	2024-03-15	2026-01-01	大陸商南京三迭紀醫藥科技有限公司	用於體內滯留的藥物劑型
CN118743817B (zh) *	2024-09-04	2025-01-21	中国农业大学	一种瘤胃持续给药系统

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3839557A (en) *	1972-01-24	1974-10-01	Lilly Co Eli	Antibiotics monensin and a204 for improving ruminant feed efficiency
US4312347A (en) *	1980-02-25	1982-01-26	Iowa State University Research Foundation, Inc.	Positive pressure drug releasing device
NZ197543A (en) *	1980-07-02	1984-12-14	Commw Scient Ind Res Org	Controlled release compositions for inclusion in intraruminal devices
US4381780A (en) *	1981-01-19	1983-05-03	Research Corporation	Sustained release delivery system
GR75160B (cs) *	1981-01-22	1984-07-13	Lilly Co Eli
JPS57156736A (en) *	1981-03-23	1982-09-28	Olympus Optical Co	Therapeutic capsule apparatus
JPS57163309A (en) *	1981-04-01	1982-10-07	Olympus Optical Co Ltd	Capsule apparatus for medical use
US4416659A (en) *	1981-11-09	1983-11-22	Eli Lilly And Company	Sustained release capsule for ruminants
AU558009B2 (en) *	1982-02-16	1987-01-15	Commonwealth Scientific And Industrial Research Organisation	Gas diffusion controlled release device
EP0149510B1 (en) *	1984-01-06	1989-03-22	Eli Lilly And Company	Sustained release device for ruminants
US4649042A (en) *	1984-05-31	1987-03-10	Eli Lilly And Company	Rumen delivery device
US4717718A (en) *	1985-08-09	1988-01-05	Alza Corporation	Device for the controlled delivery of a beneficial agent
AU591297B2 (en) *	1986-07-15	1989-11-30	Pitman-Moore Australia Limited	Intra-ruminal depot
US4867980A (en) *	1986-10-10	1989-09-19	Coopers Animal Health Australia Limited	Heavy density depot
AU596220B2 (en) *	1986-10-10	1990-04-26	Pitman-Moore Australia Limited	Heavy density depot
US4929233A (en) *	1988-08-26	1990-05-29	Alza Corporation	Implantable fluid imbibing pump with improved closure
AU615599B2 (en) *	1988-12-22	1991-10-03	Eli Lilly And Company	Methods

1992
- 1992-04-01 AU AU13969/92A patent/AU650113B2/en not_active Expired
- 1992-04-02 TW TW081102567A patent/TW404830B/zh not_active IP Right Cessation
- 1992-04-03 NO NO921304A patent/NO303374B1/no not_active IP Right Cessation
- 1992-04-03 IL IL11819392A patent/IL118193A/en not_active IP Right Cessation
- 1992-04-03 IE IE20010191A patent/IE20010191A1/en not_active IP Right Cessation
- 1992-04-03 IL IL11819292A patent/IL118192A/en not_active IP Right Cessation
- 1992-04-03 NZ NZ242225A patent/NZ242225A/en not_active IP Right Cessation
- 1992-04-03 IL IL101491A patent/IL101491A/en not_active IP Right Cessation
- 1992-04-03 PT PT100345A patent/PT100345B/pt not_active IP Right Cessation
- 1992-04-03 HU HU9201135A patent/HU217965B/hu not_active IP Right Cessation
- 1992-04-03 CA CA002065084A patent/CA2065084C/en not_active Expired - Fee Related
- 1992-04-03 FI FI921493A patent/FI114686B/fi not_active IP Right Cessation
- 1992-04-03 MX MX9201539A patent/MX9201539A/es active IP Right Grant
- 1992-04-03 CZ CS921023A patent/CZ282457B6/cs not_active IP Right Cessation
- 1992-04-03 EP EP92302997A patent/EP0507629B1/en not_active Expired - Lifetime
- 1992-04-03 DK DK92302997.9T patent/DK0507629T3/da active
- 1992-04-03 RU SU5011437A patent/RU2114577C1/ru not_active IP Right Cessation
- 1992-04-03 YU YU35792A patent/YU49098B/sh unknown
- 1992-04-03 EP EP96200392A patent/EP0715847A3/en not_active Withdrawn
- 1992-04-03 IL IL11819592A patent/IL118195A/en not_active IP Right Cessation
- 1992-04-03 NZ NZ314295A patent/NZ314295A/en not_active IP Right Cessation
- 1992-04-03 MY MYPI98000787A patent/MY135579A/en unknown
- 1992-04-03 CN CN92103383A patent/CN1056278C/zh not_active Expired - Fee Related
- 1992-04-03 AT AT92302997T patent/ATE147972T1/de not_active IP Right Cessation
- 1992-04-03 IE IE107892A patent/IE921078A1/en not_active IP Right Cessation
- 1992-04-03 DE DE69216891T patent/DE69216891T2/de not_active Expired - Fee Related
- 1992-04-03 NZ NZ280067A patent/NZ280067A/en not_active IP Right Cessation
- 1992-04-03 MY MYPI92000583A patent/MY112079A/en unknown
- 1992-04-03 NZ NZ330507A patent/NZ330507A/en not_active IP Right Cessation
- 1992-04-03 IL IL11819492A patent/IL118194A/en not_active IP Right Cessation
- 1992-04-03 ES ES92302997T patent/ES2096717T3/es not_active Expired - Lifetime
- 1992-04-03 NZ NZ264061A patent/NZ264061A/en not_active IP Right Cessation
- 1992-04-04 KR KR1019920005658A patent/KR100205666B1/ko not_active Expired - Fee Related
- 1992-04-06 US US07/863,898 patent/US5277912A/en not_active Expired - Lifetime
- 1992-04-06 JP JP08420792A patent/JP3356796B2/ja not_active Expired - Fee Related
- 1992-04-06 BR BR929201217A patent/BR9201217A/pt not_active IP Right Cessation
1993
- 1993-12-07 US US08/163,842 patent/US5562915A/en not_active Expired - Lifetime
1994
- 1994-09-08 AU AU72867/94A patent/AU672520B2/en not_active Expired
1996
- 1996-01-25 YU YU4296A patent/YU4296A/sh unknown
- 1996-05-09 IL IL11819596A patent/IL118195A0/xx unknown
- 1996-05-09 IL IL11819296A patent/IL118192A0/xx unknown
- 1996-05-09 IL IL11819496A patent/IL118194A0/xx unknown
- 1996-05-09 IL IL11819396A patent/IL118193A0/xx unknown
1997
- 1997-03-17 GR GR970400498T patent/GR3022824T3/el unknown
1999
- 1999-04-24 CN CN99106439A patent/CN1235825A/zh active Pending
- 1999-04-24 CN CN99106440A patent/CN1258501A/zh active Pending
- 1999-09-16 FI FI991970A patent/FI107315B/fi not_active IP Right Cessation
- 1999-09-21 PT PT102360A patent/PT102360B/pt not_active IP Right Cessation
2000
- 2000-10-05 FI FI20002197A patent/FI111602B/fi not_active IP Right Cessation
2002
- 2002-04-22 JP JP2002119394A patent/JP2003023972A/ja active Pending

Also Published As

Publication number	Publication date
IL118192A0 (en)	1996-09-12
DE69216891D1 (de)	1997-03-06
US5562915A (en)	1996-10-08
KR100205666B1 (ko)	1999-07-01
CA2065084A1 (en)	1992-10-06
CN1056278C (zh)	2000-09-13
RU2114577C1 (ru)	1998-07-10
PT102360A (pt)	2000-03-31
FI921493L (fi)	1992-10-06
AU7286794A (en)	1994-12-01
YU49098B (sh)	2003-12-31
CN1067810A (zh)	1993-01-13
HUT74907A (en)	1997-03-28
YU35792A (sh)	1997-07-31
PT102360B (pt)	2001-08-30
NZ280067A (en)	1997-04-24
FI111602B (fi)	2003-08-29
YU4296A (sh)	1999-03-04
IL118195A0 (en)	1996-09-12
FI20002197L (fi)	2000-10-05
NZ242225A (en)	1995-02-24
NZ330507A (en)	1998-07-28
TW404830B (en)	2000-09-11
CA2065084C (en)	2000-12-12
JP2003023972A (ja)	2003-01-28
EP0507629A1 (en)	1992-10-07
DE69216891T2 (de)	1997-05-28
DK0507629T3 (da)	1997-06-30
HU217965B (hu)	2000-05-28
KR920019335A (ko)	1992-11-19
ATE147972T1 (de)	1997-02-15
US5277912A (en)	1994-01-11
NO921304L (no)	1992-10-06
FI921493A0 (fi)	1992-04-03
IL118194A (en)	1998-09-24
IL118193A (en)	1998-08-16
FI114686B (fi)	2004-12-15
EP0507629B1 (en)	1997-01-22
GR3022824T3 (en)	1997-06-30
PT100345A (pt)	1994-04-29
IL118195A (en)	1998-09-24
ES2096717T3 (es)	1997-03-16
IL101491A (en)	1998-02-08
IE20010191A1 (en)	2002-11-27
FI107315B (fi)	2001-07-13
MX9201539A (es)	1992-10-01
CN1235825A (zh)	1999-11-24
JP3356796B2 (ja)	2002-12-16
IL118193A0 (en)	1996-09-12
IE921078A1 (en)	1992-10-07
HU9201135D0 (en)	1992-06-29
JPH0597659A (ja)	1993-04-20
BR9201217A (pt)	1992-12-01
NZ264061A (en)	1996-06-25
IL118194A0 (en)	1996-09-12
FI19991970L (fi)	1999-09-16
CZ282457B6 (cs)	1997-07-16
MY135579A (en)	2008-05-30
NZ314295A (en)	1998-07-28
PT100345B (pt)	2000-02-29
EP0715847A2 (en)	1996-06-12
AU672520B2 (en)	1996-10-03
IL118192A (en)	1998-08-16
CN1258501A (zh)	2000-07-05
MY112079A (en)	2001-04-30
AU650113B2 (en)	1994-06-09
CS102392A3 (en)	1992-10-14
AU1396992A (en)	1992-10-08
EP0715847A3 (en)	2003-11-19
NO921304D0 (no)	1992-04-03

Legal Events

Date	Code	Title	Description
2005-11-28	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO303374B1 (no)	1998-07-06	Kapsel med forsinket frigj°ring
JP3738033B2 (ja)	2006-01-25	ウシ属動物に対する体液感応性ソマトトロピンの送出のための浸透システム
AU2004210542C1 (en)	2009-01-08	Dosage form, device and methods of treatment
AU708219B2 (en)	1999-07-29	Sustained release capsule and formulations
AU734462B2 (en)	2001-06-14	Sustained release capsule and formulations
HU219460B (hu)	2001-04-28	Eljárás kérődző állatok bendőjében valamely hatóanyag tartós felszabadítására alkalmas kapszula előállítására
HK1029057A (en)	2001-03-23	Sustained release capsule and formulations